Literature DB >> 35401960

Patient ownership of primary biliary cholangitis long-term management.

Jessica Leighton1, Collette Thain2, Robert Mitchell-Thain2, Jessica K Dyson1, David E Jones1.   

Abstract

Objective: Patient ownership of disease is vital in rare diseases like primary biliary cholangitis (PBC). This survey of UK members of the PBC foundation aimed to assess patients' perception of their disease management, focusing on key biomarkers and problematic symptoms. Design: Registered PBC foundation members were surveyed on their experiences on their most recent clinic visit, covering the type of hospital and clinician and whether biochemical response and symptom burden were discussed, including who initiated these conversations. Respondents were also asked about their willingness to initiate these conversations.
Results: Across 633 respondents, 42% remembered discussing alkaline phosphatase, the key biochemical response measure, and the majority of discussions were initiated by the healthcare provider. 56% of respondents remembered discussing itch, a key PBC symptom. There was no distinction between the grade of healthcare professional, but both patients and clinicians were significantly more likely to discuss symptoms over disease progression. Reassuringly, 84% of respondents felt willing to initiate conversations about their illness, regardless of the grade of managing clinician. Conclusions: This work lays a positive foundation for patient education and empowerment projects, likely to improve clinical outcomes. Key aspects of management (biochemical response to treatment and symptom burden) should be emphasised as topics of discussion to both patients and clinicians managing PBC. We suggest a simple cue card to prompt patient-led discussion. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  autoimmune liver disease; primary biliary cirrhosis

Year:  2020        PMID: 35401960      PMCID: PMC8989000          DOI: 10.1136/flgastro-2019-101324

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  6 in total

1.  Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom.

Authors:  Vinod S Hegade; George F Mells; Holly Fisher; Stuart Kendrick; Julia DiBello; Kim Gilchrist; Graeme J Alexander; Gideon M Hirschfield; Richard N Sandford; David E J Jones
Journal:  Clin Gastroenterol Hepatol       Date:  2018-12-14       Impact factor: 11.382

2.  Meta-analysis: chronic disease self-management programs for older adults.

Authors:  Joshua Chodosh; Sally C Morton; Walter Mojica; Margaret Maglione; Marika J Suttorp; Lara Hilton; Shannon Rhodes; Paul Shekelle
Journal:  Ann Intern Med       Date:  2005-09-20       Impact factor: 25.391

3.  Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid.

Authors:  Marco Carbone; George F Mells; Greta Pells; Muhammad F Dawwas; Julia L Newton; Michael A Heneghan; James M Neuberger; Darren B Day; Samantha J Ducker; Richard N Sandford; Graeme J Alexander; David E J Jones
Journal:  Gastroenterology       Date:  2012-12-12       Impact factor: 22.682

4.  Are Clinicians Ready for Safe Use of Stratified Therapy in Primary Biliary Cholangitis (PBC)? A Study of Educational Awareness.

Authors:  Laura Jopson; Amardeep Khanna; Patricia Peterson; Elaine Rudell; Margaret Corrigan; David Jones
Journal:  Dig Dis Sci       Date:  2018-05-08       Impact factor: 3.199

5.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

Authors:  Frederik Nevens; Pietro Andreone; Giuseppe Mazzella; Simone I Strasser; Christopher Bowlus; Pietro Invernizzi; Joost P H Drenth; Paul J Pockros; Jaroslaw Regula; Ulrich Beuers; Michael Trauner; David E Jones; Annarosa Floreani; Simon Hohenester; Velimir Luketic; Mitchell Shiffman; Karel J van Erpecum; Victor Vargas; Catherine Vincent; Gideon M Hirschfield; Hemant Shah; Bettina Hansen; Keith D Lindor; Hanns-Ulrich Marschall; Kris V Kowdley; Roya Hooshmand-Rad; Tonya Marmon; Shawn Sheeron; Richard Pencek; Leigh MacConell; Mark Pruzanski; David Shapiro
Journal:  N Engl J Med       Date:  2016-08-18       Impact factor: 91.245

6.  Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.

Authors:  Marco Carbone; Alessandra Nardi; Steve Flack; Guido Carpino; Nikoletta Varvaropoulou; Caius Gavrila; Ann Spicer; Jonathan Badrock; Francesca Bernuzzi; Vincenzo Cardinale; Holly F Ainsworth; Michael A Heneghan; Douglas Thorburn; Andrew Bathgate; Rebecca Jones; James M Neuberger; Pier Maria Battezzati; Massimo Zuin; Simon Taylor-Robinson; Maria F Donato; John Kirby; Robert Mitchell-Thain; Annarosa Floreani; Fotios Sampaziotis; Luigi Muratori; Domenico Alvaro; Marco Marzioni; Luca Miele; Fabio Marra; Edoardo Giannini; Eugenio Gaudio; Vincenzo Ronca; Giulia Bonato; Laura Cristoferi; Federica Malinverno; Alessio Gerussi; Deborah D Stocken; Heather J Cordell; Gideon M Hirschfield; Graeme J Alexander; Richard N Sandford; David E Jones; Pietro Invernizzi; George F Mells
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-07-13
  6 in total
  1 in total

1.  The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study.

Authors:  David E J Jones; Aaron Wetten; Ben Barron-Millar; Laura Ogle; George Mells; Steven Flack; Richard Sandford; John Kirby; Jeremy Palmer; Sophie Brotherston; Laura Jopson; John Brain; Graham R Smith; Steve Rushton; Rebecca Jones; Simon Rushbrook; Douglas Thorburn; Stephen D Ryder; Gideon Hirschfield; Jessica K Dyson
Journal:  EBioMedicine       Date:  2022-05-21       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.